Efficacy and safety of long‑course tacrolimus treatment for idiopathic membranous nephropathy

Di,Jia; Qian,Qing; Yang,Min; Jiang,Yaping; Zhou,Hua; Li,Min; Zou,Yun

doi:10.3892/etm.2018.6211

Efficacy and safety of long‑course tacrolimus treatment for idiopathic membranous nephropathy

Authors:
- Jia Di
- Qing Qian
- Min Yang
- Yaping Jiang
- Hua Zhou
- Min Li
- Yun Zou
View Affiliations

Affiliations: Department of Nephrology, The First People's Hospital of Changzhou, Changzhou, Jiangsu 213003, P.R. China, Department of Pharmacy, The First People's Hospital of Changzhou, Changzhou, Jiangsu 213003, P.R. China
Published online on: May 23, 2018 https://doi.org/10.3892/etm.2018.6211
Pages: 979-984

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Abstract. The aim of the present study was to observe the efficacy and safety of long‑course treatment with tacrolimus combined with low‑dose corticosteroids for idiopathic membranous nephropathy (IMN). A total of 76 patients with IMN diagnosed by renal biopsy between March 2012 and January 2016 form The First People's Hospital of Changzhou (Changzhou, China) were selected and randomly divided into a short‑course group and a long‑course group (each, n=38). Patients in the short‑course group were treated with hormone combined with tacrolimus for 12 months, whereas those in the long‑course group received the same treatment for 24 months. The efficacy, safety and recurrence of the two groups of patients were observed, and serum ALB, urine protein, Scr and blood glucose were assessed once a month for 24 months by measuring blood biochemistry. A total of 11 patients exhibited adverse effects, 6 of whom were serious and as such were excluded from the study. In the short‑course group, 8 of 35 patients demonstrated complete remission (CR), 17 patients exhibited partial remission (PR) and the remaining 10 patients had no remission (NR); however the disease recurred in 8 patients following treatment. In the long‑course group, 16 of 35 patients exhibited CR, 14 patients demonstrated PR and the remaining 5 patients had NR. Furthermore, the disease recurred in 4 patients following treatment. Significant differences were observed in urine protein and serum ALB at 18 and 24 months following treatment between the two groups while Scr and blood glucose had no significant differences at any time point. It was concluded that long‑course tacrolimus combined with low‑dose hormone effectively treats idiopathic membranous nephropathy and that therapy demonstrated a relatively high remission rate, and the recurrence rate of the disease is low.

View Figures

View References

1	Massry SG and Glassock RJ: Massry & Glassock's textbook of nephrology. Lippincott Williams & Wilkins; Philadelphia, PA; pp. 701–713. 2001
2	Ronco P and Debiec H: Pathogenesis of membranous nephropathy: Recent advances and future challenges. Nat Rev Nephrol. 8:203–213. 2012. View Article : Google Scholar : PubMed/NCBI
3	Waldman M and Austin HA III: Treatment of idiopathic membranous nephropathy. J Am Soc Nephrol. 23:1617–1630. 2012. View Article : Google Scholar : PubMed/NCBI
4	Kidney Disease: Improving Global Outcomes (KDIGO): KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2:139–274. 2012.
5	Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N and Remuzzi G: Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review. Am J Kidney Dis. 44:385–401. 2004. View Article : Google Scholar : PubMed/NCBI
6	Schieppati A, Perna A, Zamora J, Giuliano GA, Braun N and Remuzzi G: Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 18:CD0042932004.
7	Scott LJ, McKeage K, Keam SJ and Plosker GL: Tacrolimus: A further update of its use in the management of organ transplantation. Drugs. 63:1247–1297. 2003. View Article : Google Scholar : PubMed/NCBI
8	Ramachandran R, Hn HK, Kumar V, Nada R, Yadav AK, Goyal A, Kumar V, Rathi M, Jha V, Gupta KL, et al: Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial. Nephrology (Carlton). 21:139–146. 2016. View Article : Google Scholar : PubMed/NCBI
9	Ramachandran R, Kumar V, Nada R, Kohli HS, Jha V and Gupta KL: Tacrolimus with corticosteroids is inferior to modified Ponticelli regimen in the management of primary membranous nephropathy: Results at 2 years of randomization. Nephrol Dial Transplant. 31(Suppl 1): i772016. View Article : Google Scholar
10	Xu J, Zhang W, Xu Y, Shen P, Ren H, Wang W, Li X, Pan X and Chen N: Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: A randomized, prospective, controlled trial. Contrib Nephrol. 181:152–162. 2013. View Article : Google Scholar : PubMed/NCBI
11	Debiec H, Guigonis V, Mougenot B, Decobert F, Haymann JP, Bensman A, Deschênes G and Ronco PM: Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med. 346:2053–2060. 2002. View Article : Google Scholar : PubMed/NCBI
12	Qin W, Beck LH Jr, Zeng C, Chen Z, Li S, Zuo K, Salant DJ and Liu Z: Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 22:1137–1143. 2011. View Article : Google Scholar : PubMed/NCBI
13	Prunotto M, Carnevali ML, Candiano G, Murtas C, Bruschi M, Corradini E, Trivelli A, Magnasco A, Petretto A, Santucci L, et al: Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol. 21:507–519. 2010. View Article : Google Scholar : PubMed/NCBI
14	Chen Y, Schieppati A, Cai G, Chen X, Zamora J, Giuliano GA, Braun N and Perna A: Immunosuppression for membranous nephropathy: A systematic review and meta-analysis of 36 clinical trials. Clin J Am Soc Nephrol. 8:787–796. 2013. View Article : Google Scholar : PubMed/NCBI
15	Chen M, Li H, Li XY, Lu FM, Ni ZH, Xu FF, Li XW, Chen JH and Wang HY; Chinese Nephropathy Membranous Study Group: Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: A multicenter randomized controlled trial. Am J Med Sci. 339:233–238. 2010. View Article : Google Scholar : PubMed/NCBI
16	Qi JC, Liu PG, Wang C, Zheng AD and Wan Z: Tacrolimus protects vascular endothelial cells from injuries caused by Ox-LDL by regulating endoplasmic reticulum stress. Eur Rev Med Pharmacol Sci. 21:3966–3973. 2017.PubMed/NCBI
17	Santosh T, Liu H and Liu B: Effect of tacrolimus in idiopathic membranous nephropathy: A meta-analysis. Chin Med J (Engl). 127:2693–2699. 2014.PubMed/NCBI
18	Ballarin J, Poveda R, Ara J, Pérez L, Calero F, Grinyó JM and Romero R: Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: Results of a pilot study. Nephrol Dial Transplant. 22:3196–3201. 2007. View Article : Google Scholar : PubMed/NCBI
19	Arikan H, Koc M, Cakalagaoglu F, Eren Z, Segal MS, Tuglular S, Ozener C and Akoglu E: Tacrolimus rescue therapy in resistant or relapsing cases of primary glomerulonephritis. J Nephrol. 21:713–721. 2008.PubMed/NCBI
20	Caro J, Gutiérrez-Solís E, Rojas-Rivera J, Agraz I, Ramos N, Rabasco C, Espinosa M, Valera A, Martín M, Frutos MÁ, et al: Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus. Nephrol Dial Transplant. 30:467–474. 2015. View Article : Google Scholar : PubMed/NCBI
21	Yuan H, Liu N, Sun GD, Jia Y, Luo P and Miao LN: Effect of prolonged tacrolimus treatment in idiopathic membranous nephropathy with nephrotic syndrome. Pharmacology. 91:259–266. 2013. View Article : Google Scholar : PubMed/NCBI
22	Yağmurdur MC, Sevmis S, Emiroğlu R, Moray G, Bilgin N and Haberal M: Tacrolimus conversion in kidney transplant recipients: Analysis of 107 patients. Transplant Proc. 36:144–147. 2004. View Article : Google Scholar : PubMed/NCBI
23	He L, Peng Y, Liu H, Liu Y, Yuan S, Liu F, Yang D, Liu H, Chen X, Shao J and Fu M: Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids. J Nephrol. 26:564–571. 2013. View Article : Google Scholar : PubMed/NCBI